Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | CA4 | P22748 | 5/20 | 0.40 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401034 | 0.98 | ALDH1A1 (0.43) | ALDH1A1TSHRCA1CA2CA4 | |
| SCHEMBL5039623 | 0.94 | ALDH1A1 (0.39) | ALDH1A1TSHRCA1CA2CA4 | |
| SCHEMBL22958440 | 0.88 | DGKA (0.41) | ALDH1A1TSHRCA1CA2CA4 | |
| SCHEMBL6029546 | 0.86 | ALDH1A1 (0.34) | ALDH1A1TSHRCA1CA2CA4 | |
| SCHEMBL396155 | 0.83 | CA12 (0.41) | ALDH1A1CA1CA2CA4CA12 | |
| SCHEMBL400377 | 0.83 | ALDH1A1 (0.43) | ALDH1A1TSHRTP53 | |
| SCHEMBL2009739 | 0.81 | CA12 (0.44) | ALDH1A1CA1CA2CA4CA12 | |
| SCHEMBL399991 | 0.81 | ALDH1A1 (0.48) | ALDH1A1TSHRCA1CA2CA4 | |
| SCHEMBL14894607 | 0.79 | ALDH1A1 (0.52) | ALDH1A1TSHR | |
| Methane SCHEMBL2010264 | 0.79 | ALDH1A1 (0.47) | ALDH1A1TSHRCA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125379-A1 | PRODRUG OF JAK KINASE INHIBITOR | E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4582425-A1 | PRODRUG OF JAK KINASE INHIBITOR | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd (CN) | 2025-07-09 | — | — | EP | disclosed |
| CN-102099330-B | Nitric oxide donating prostamides | NICOX SA | 2014-04-30 | — | — | CN | disclosed |
| CN-103260424-A | Use of nitrooxy organic molecules in feed for reducing methane emission in ruminants, and/or to improve ruminant performance | DSM IP ASSETS BV | 2013-08-21 | — | — | CN | disclosed |
| EP-2274279-B1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX SA (FR) | 2013-07-31 | — | — | EP | disclosed |
| US-8101658-B2 | Nitric oxide donating prostamides | NICOX S.A. (FR) | 2012-01-24 | — | — | US | disclosed |
| CN-102099330-A | Nitric oxide donating prostamides | NICOX SA | 2011-06-15 | — | — | CN | disclosed |
| US-20110092590-A1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX S.A. (FR) | 2011-04-21 | — | — | US | disclosed |
| EP-2274279-A1 | NITRIC OXIDE DONATING PROSTAMIDES | Nicox S.A. (FR) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009136281-A1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX S.A. (FR) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125379-A1 | PRODRUG OF JAK KINASE INHIBITOR | JAK1, JAK2, JAK3 | ALDH1A1 1710/4885TSHR 519/4885CA1 2284/4885 |
| US-20110092590-A1 | NITRIC OXIDE DONATING PROSTAMIDES | PTGIS, PTGIR, NOS2 | ALDH1A1 936/4885TSHR 3475/4885CA1 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.